2023 - Research.com Neuroscience in United Kingdom Leader Award
His primary scientific interests are in Parkinson's disease, Deep brain stimulation, Neuroscience, Dementia and Disease. His Parkinson's disease study deals with the bigger picture of Internal medicine. His Deep brain stimulation research focuses on Subthalamic nucleus in particular.
His Neuroscience study integrates concerns from other disciplines, such as Neurodegeneration and Insulin resistance. His Dementia research incorporates themes from Risk factor, Cohort and Bioinformatics. His studies in Disease integrate themes in fields like Genetics and Pathological.
Thomas Foltynie focuses on Parkinson's disease, Deep brain stimulation, Neuroscience, Subthalamic nucleus and Disease. Thomas Foltynie combines subjects such as Dementia and Physical medicine and rehabilitation with his study of Parkinson's disease. In his study, which falls under the umbrella issue of Deep brain stimulation, Tics is strongly linked to Tourette syndrome.
The study of Neuroscience is intertwined with the study of Beta in a number of ways. His research investigates the connection between Disease and topics such as Cohort that intersect with problems in Pediatrics. His biological study spans a wide range of topics, including Endocrinology, Oncology and Pathology.
Parkinson's disease, Deep brain stimulation, Disease, Neuroscience and Physical medicine and rehabilitation are his primary areas of study. The subject of his Parkinson's disease research is within the realm of Internal medicine. His work deals with themes such as Neurology, Oncology and Gene mutation, which intersect with Internal medicine.
His research in Deep brain stimulation intersects with topics in Stimulation, Dyskinesia and Tourette syndrome. The various areas that he examines in his Disease study include Incidence, Bioinformatics, Diabetes mellitus, Intensive care medicine and Pharmacotherapy. His Physical medicine and rehabilitation research is multidisciplinary, incorporating perspectives in Anterior cingulate cortex, Ventral striatum, Hypokinesia and Motor dysfunction.
Thomas Foltynie mostly deals with Parkinson's disease, Disease, Deep brain stimulation, Internal medicine and Subthalamic nucleus. His work carried out in the field of Parkinson's disease brings together such families of science as Genome-wide association study and Bioinformatics. His Disease study combines topics from a wide range of disciplines, such as Incidence, Diabetes mellitus, Type 2 diabetes, Intensive care medicine and Genetic association.
His Deep brain stimulation research is multidisciplinary, incorporating elements of Orbitofrontal cortex, Physical medicine and rehabilitation, Resting state fMRI, Neuroscience and Tourette syndrome. His Internal medicine research integrates issues from Oncology and Gene mutation. Thomas Foltynie interconnects Phonation, Audiology, Functional magnetic resonance imaging, Verbal fluency test and Direct pathway of movement in the investigation of issues within Subthalamic nucleus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
C. H. Williams-Gray;T. Foltynie;C. E. G. Brayne;T. W. Robbins.
Brain (2007)
Adaptive deep brain stimulation in advanced Parkinson disease
Simon Little;Alex Pogosyan;Spencer Neal;Baltazar Zavala.
Annals of Neurology (2013)
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Caroline H. Williams-Gray;Jonathan R. Evans;An Goris;An Goris;Thomas Foltynie.
Brain (2009)
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.
D. Aarsland;K. Bronnick;C. Williams-Gray;D. Weintraub.
Neurology (2010)
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study
Thomas Foltynie;Carol E. G. Brayne;Trevor W. Robbins;Roger A. Barker.
Brain (2004)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
Mike A Nalls;Cornelis Blauwendraat;Costanza L Vallerga;Karl Heilbron.
Lancet Neurology (2019)
Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach
S J G Lewis;T Foltynie;A D Blackwell;T W Robbins.
Journal of Neurology, Neurosurgery, and Psychiatry (2005)
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Caroline H Williams-Gray;Sarah L Mason;Jonathan R Evans;Thomas Foltynie.
Journal of Neurology, Neurosurgery, and Psychiatry (2013)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda;Kate Maclagan;Simon S Skene;Martha Bajwa-Joseph.
The Lancet (2017)
Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson's disease
Vladimir Litvak;Vladimir Litvak;Ashwani Jha;Ashwani Jha;Alexandre Eusebio;Robert Oostenveld.
Brain (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University College London
University College London
Umeå University
University of Oxford
University of Cambridge
University College London
University College London
University College London
University College London
Newcastle University
University of Oxford
University of Groningen
INRA Biology Center for Population Management (CBGP)
Spanish National Research Council
Cardiff University
University of Macau
University of Massachusetts Medical School
University of British Columbia
Netherlands Institute for Space Research
University of Wyoming
Savannah River National Laboratory
University of Arizona
Walter and Eliza Hall Institute of Medical Research
University of British Columbia
Columbia University
Max Planck Society